Entrada Therapeutics Inc (TRDA) has provided an announcement.
Entrada Therapeutics has announced promising preliminary results from a Phase 1 clinical trial for ENTR-601-44, a potential treatment for Duchenne muscular dystrophy (DMD). The trial showed the drug’s safety and tolerability, with no serious adverse events reported among the 32 male volunteers. Positive pharmacokinetic and pharmacodynamic outcomes were observed, including exon skipping in muscle tissue. Based on these initial findings, the company plans to proceed with regulatory applications for global Phase 2 trials targeting different DMD patient groups, emphasizing the potential of ENTR-601-44 to be a transformative treatment.
See more data about TRDA stock on TipRanks’ Stock Analysis page.
